Clinical Trial SuccessKazia announced additional positive data from a triple negative breast cancer (TNBC) patient treated with paxalisib, finding an 86% reduction in tumor burden.
Financial PositionFollowing a $2M capital raise, Kazia had a cash balance sufficient to carry operations into the first quarter of 2026, supporting ongoing developments.
Market ConfidenceAnalyst's 12-month price target for Kazia has increased to $20, reflecting confidence in paxalisib's potential in both triple-negative breast cancer and glioblastoma multiforme.